Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2009

View Archived Issues

NIAID awards Cleveland BioLabs grant for protectan CBLB-502 research

Novel mPGES-1 inhibitors identified by NovaSAID for RA and other conditions

Perlegen Sciences launches BrevaGen breast cancer risk stratification test

FDA grants approval to Cepheid to market Xpert HemosIL FII and FV test

Abbott to acquire Solvay for EUR 4.5 billion in cash

Centocor's Stelara approved by the FDA for moderate to severe plaque psoriasis

Galapagos expands drug discovery collaboration with Schering-Plough

FDA grants priority review to sNDA of Cephalon's Nuvigil for jet lag disorder

Medivation initiates phase III MDV-3100 trial in advanced prostate cancer

BioLineRx reports final results from EAGLE trial in schizophrenia

Campath meets primary endpoint in phase III combination therapy trial for CLL

Chelsea Therapeutics reports preliminary phase III data of droxidopa for orthostatic hypotension

Keryx reports results of open-label extension study of Zerenex for hyperphosphatemia

Ticagrelor reduces cardiovascular death and heart attacks in patients with ACS

CHMP issues positive opinion for Yondelis in combination with Caelyx in ovarian cancer

Anti-RANKL antibody reduces breast cancer metastasis to bone in novel mouse model

Blocking RANK-L activity with ALX-0141, a potential treatment for bone resorption disorders

Phase II clinical benefit of everolimus in patients with recurrent endometrial carcinoma

New antimycobacterial calpinactam discovered at Kitasato University

Natural product AS-2077715 active against Trichophyton spp.

Icotinib hydrochloride safe and active in NSCLC patients in phase I/IIa trial

Boehringer Ingelheim presents MCH-R1 receptor antagonists for treating obesity

Opioid receptor antagonists for the treatment of pain presented by Alkermes

Novel compounds for the treatmemt of HCV infection claimed by Bristol-Myers Squibb

Stockholders from Raptor Pharmaceuticals and TorreyPines Therapeutics approve merger

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...